Clinical and molecular aspects of glucocorticoid resistant asthma by Corrigan, Chris J & Loke, Tuck-Kay
© 2007 Dove Medical Press Limited.   All rights reserved
Therapeutics and Clinical Risk Management 2007:3(5) 771–787 771
REVIEW




Division of Asthma, Allergy and 
Lung Biology, King’s College London, 
London, England, UK; MRC and 
Asthma UK Centre in Allergic 
Mechanisms of Asthma, King’s College 
London, London, England, UK
Correspondence: Chris Corrigan
5th Floor, Thomas Guy House, Guy’s 
Hospital, London SE1 9RT, UK
Tel +44 207 188 0599
Fax +44 207 403 8640
Email chris.corrigan@kcl.ac.uk
Abstract: This paper is an overview of the diagnosis, differential diagnosis and cellular and 
molecular mechanisms of glucocorticoid resistant asthma. It addresses the clinical deﬁ  nition 
and rationale for the diagnosis of therapy resistant asthma. It purports that, since glucocorticoid 
resistant asthmatics are not globally physiologically glucocorticoid resistant, then the phe-
nomenon is most likely acquired, probably in immune cells (and most probably in T cells and 
monocyte/macrophages), as a result of local inﬂ  ammatory and environmental inﬂ  uences. The 
molecular mechanisms which have been uncovered to date which could account for glucocor-
ticoid resistance are discussed, in particular the roles of AP-1 and p38 MAP kinase signaling, 
the role of the β-isoform of the glucocorticoid receptor and the role of histone proteins and 
DNA folding. Finally, there are suggestions for clinical management of these patients based 
on accumulated evidence.
Introduction
Glucocorticoids are very effective therapy for asthma and numerous studies have shown 
that they reduce asthma symptoms, exacerbations and bronchial hyperresponsiveness. 
The beneﬁ  t/risk ratio of glucocorticoid therapy was enhanced further in the 1960’s 
when topical delivery devices were introduced. Inhaled glucocorticoids are now the 
ﬁ  rst line therapy in patients with all but the mildest disease.
The vast majority of asthmatics are controlled satisfactorily with regular inhaled 
glucocorticoids with or without the addition of short- or long-acting bronchodilators. 
In such patients, particularly those on low to moderate dosages of inhaled glucocor-
ticoids, it is hard to conceive of a safer or more effective therapy.
Unfortunately, however, a proportion of patients develop severe disease which is 
relatively or totally refractory to glucocorticoid therapy. The possible etiology of this 
condition will be discussed in subsequent paragraphs, but the existence of the phenom-
enon implies that asthma is heterogeneous in terms of its susceptibility to inhibition 
by glucocorticoids, and possibly therefore also in terms of its etiology.
While the percentages of patients with glucocorticoid resistant asthma are small, 
these patients consume a signiﬁ  cant proportion of medical resources in terms of both 
time and money (Buist 1995). Regardless of costs, there is an urgent need to provide 
alternative therapies for these patients, who often have severely impaired quality of 
life not only from the severity of their symptoms but from the effects of excessive 
glucocorticoid exposure.
Difﬁ  cult asthma
Deﬁ  nition
Although any clinician managing asthmatic patients will have a clear picture of “dif-
ﬁ  cult to treat” disease, it is in fact extraordinarily difﬁ  cult to deﬁ  ne this condition 
accurately, particularly for the purposes of research.Therapeutics and Clinical Risk Management 2007:3(5) 772
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Definition of “difficult asthma” could include the 
following:
• Conﬁ  rmation of the diagnosis of asthma
•  An unusually poor response to therapy
•  Chronicity of the problem.
Problems arise with all of these concepts. Obviously it is 
essential to be as certain as possible of a primary diagnosis 
of asthma. This diagnosis of course rests on a clinical history 
of typical symptoms and physiological evidence of variable 
and reversible airways obstruction. Often, however, on 
presentation to a specialist, it may not be possible to obtain 
contemporary evidence of these features if the patient is 
already established on therapy. Clearly it is essential to search 
for and eliminate other possible alternative or associated 
diagnoses (Table 1). Allergic bronchopulmonary aspergil-
losis and pulmonary eosinophilic syndromes (for example, 
pulmonary eosinophilia or Churg-Strauss syndrome) may be 
considered unique diseases which encompass some of the 
clinical features of asthma and which are often difﬁ  cult to 
treat: these are probably best considered outside the deﬁ  nition 
of “difﬁ  cult” asthma. Vocal cord dysfunction characterized 
by paradoxical adduction of the vocal cords may masquerade 
as and co-exist with asthma (Newman et al 1995). Other 
respiratory conditions such as chronic bronchitis or bron-
chiectasis may also co-exist with asthma, but there are very 
few studies assessing the effect of these in the long term on 
asthma severity or control.
“Resistance to therapy” is usually identiﬁ  ed as failure of 
asthma “control” despite therapy. This does, however, imply 
that all patients who are resistant to glucocorticoid therapy 
will necessarily have severe disease, which may not be the 
case. It also begs the question of what is used to deﬁ  ne asthma 
“control”. This is usually assessed in terms of symptoms and 
requirement for short-acting β2-agonist medication. Patients 
vary in their perception of airﬂ  ow limitation and poor per-
ceivers may be particularly prone to severe attacks (Kikuchi 
et al 1994). Other techniques commonly used to deﬁ  ne 
asthma “control” include objective monitoring of airways 
obstruction and the numbers of exacerbations experienced 
by patients deﬁ  ned according to various criteria (such as, for 
example, those requiring systemic glucocorticoid therapy). 
The international guidelines (Global Initiative for Asthma 
1995) deﬁ  ne asthma severity in terms of airways obstruction 
as measured by PEF or FEV1. Nevertheless, the presence of 
persistent airways obstruction does not necessarily reﬂ  ect 
loss of asthma “control”. The value of using asthma bio-
markers to assess the amount of airways inﬂ  ammation and 
the relationship of these measurements to asthma control is 
also currently under close scrutiny. There is little evidence to 
date, however, that short-term measurements of biomarkers 
can predict the severity and chronicity of symptoms. Conse-
quently, the concept of “difﬁ  cult asthma” at present requires 
our third dimension of chronicity of observation. Increas-
ingly, the amount of inhaled glucocorticoid and other therapy 
needed for the control of asthma, rather than quantiﬁ  cation of 
symptoms or of lung function is being used to deﬁ  ne asthma 
severity (Cockcroft and Swystun 1996).
A number of factors may contribute to poor asthma 
“control”, and must be taken into account before label-
ing the patient as glucocorticoid refractory or resistant 
(Table 2). Since response to therapy is part of the deﬁ  nition 
of “difﬁ  cult” asthma, the question of patient adherence to 
therapy must be considered. Compliance with inhaled glu-
cocorticoid therapy in asthma has been reported to be very 
poor (Kelloway et al 1994; Robinson et al 2003) and it might 
be expected, although there is actually little hard evidence 
(Cochrane 1992; Milgrom et al 1996) that this contributes 
to poor asthma control. Insufﬁ  cient therapy is probably a 
much bigger contributor to poor asthma control worldwide 
(Rabe et al 2004). Psychosocial factors, which may be linked 
with or compounded by poor patient compliance and lack of 
appropriate medical care (Miller and Strunk 1989; Wareham 







Cystic ﬁ  brosis
Recent aspiration (particularly in handicapped children)
Developmental abnormalities of the upper airway
Immunoglobulin deﬁ  ciencies
Primary ciliary dyskinesia
In adults





Chronic obstructive pulmonary disease
Congestive cardiac failure




As part of the asthmatic diathesis
Allergic bronchopulmonary aspergillosis
Pulmonary eosinophilic syndromes
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et al 1993; Chung et al 1999; American Thoracic Society 
2000) have also been implicated in poor asthma control and 
asthma deaths. Incorrect diagnosis of respiratory symptoms 
as asthma is a cause of apparent poor responsiveness to 
asthma therapy, and this is not as uncommon as might be 
expected, even in specialist asthma centres (Robinson et al 
2000). Although a precise mechanistic link between gastro-
esophageal reﬂ  ux and a decline in asthma control is not 
established, varying degrees of improvement in asthma have 
been observed when concomitant gastro-esophageal reﬂ  ux 
has been treated (Spaulding et al 1982). Targeted treatment 
of rhinosinusitis, often present concurrently with asthma, can 
lead to speciﬁ  c improvement in asthma control (Corren et al 
1982). Although attention to these comorbid factors seems 
pertinent, there is little evidence that they exert a global 
impact on the response of asthmatics to therapy: indeed one 
study (Heaney et al 2003), although showing a prevalence 
of comorbid conditions in patients with poorly controlled 
asthma, failed to show that such conditions were more preva-
lent in asthmatics who responded poorly to glucocorticoids. 
Moreover, targeted treatment of identiﬁ  ed comorbidities 
barely altered asthma-related quality of life in those patients 
with glucocorticoid-insensitive disease.
Clinical and pathophysiological 
phenotypes of “difﬁ  cult” asthma
Studies attempting to delineate clinical phenotypes of “dif-
ﬁ  cult” asthma are ongoing in the United States and Europe 
(ENFUMOSA 2003; Dolan et al 2004; Miller et al 2005). 
The ENFUMOSA study (ENFUMOSA 2003) showed that 
severe asthmatics were more likely to be female, more likely 
to be aspirin sensitive and less likely to be atopic. Although 
some clinical subgroups such as “brittle” asthmatics and 
glucocorticoid resistant asthmatics are recognized as being 
difﬁ  cult to treat, these studies have not yet provided a viable 
framework upon which to predict responsiveness to therapy 
on clinical grounds.
Attempts have also been made to delineate pathophysi-
ological features of asthma which predict a poor response to 
therapy. The problem with such studies in severe asthmatics 
is that it is difﬁ  cult to discriminate a priori abnormalities from 
the effects of the high dosages of glucocorticoid and other 
therapies that these patients are inevitably receiving. Much 
circumstantial evidence implicates eosinophils in asthma 
pathogenesis, although as with all inﬂ  ammatory leukocytes 
the precise mechanisms by which these cells cause the clinical 
features of asthma, and why these mechanisms might be ther-
apy resistant, remain unclear. One study described a group 
of apparently therapy resistant severe asthmatics with high 
numbers of airways eosinophils (Silkoff et al 2005), but there 
is evidence (ten Brinke et al 2004) that such patients may 
respond if treated with sufﬁ  ciently high dosages of glucocor-
ticoid. On the other hand, Wenzel and colleagues (Wenzel 
et al 1997, 1999) have shown that it is possible to delineate 
groups of severe, glucocorticoid dependent asthmatics with 
numbers of airways eosinophils within the range observed 
in normal controls. One of these studies suggested that these 
patients also had increased airways neutrophils, while the 
other did not. The airways changes associated with asthma 
which are collectively termed “remodeling” (lay down of new 
proteins, mucous hyperplasia, neovascularisation, smooth 
muscle hypertrophy/hyperplasia) could conceivably be 
resistant to therapy and cause irreversible airways blockage, 
although this has never been formally demonstrated. Clini-
cally, patients with severe asthma and irreversible airways 
obstruction show tomographic abnormalities suggestive of 
remodeling (Bumbacea et al 2004). Whether remodeling is 
caused by inﬂ  ammatory cells or cytokines, or both, is still 
not clear. In animals, over expression of the cytokine IL-13 
alone in the airways reproduced all the features of airways 
remodeling (Kibe et al 2003); glucocorticoid administra-
tion abolished the associated cellular inﬁ  ltrate but not the 
remodeling changes. In human studies, anti-IL-5 therapy was 
shown to reduce lay down of extracellular matrix proteins 
in the lungs while partly but not completely abolishing the 
inﬁ  ltration of eosinophils (Flood-Page et al 2003), leaving 
the question open whether or not leukocytes such as eosino-
phils play an indispensable role in this process. It has been 
suggested that one etiological factor in intrinsic asthma is 
autoimmune attack of the airways, for example by autoanti-
bodies (Lasalle et al 1993; Nahm et al 2002).
In summary, despite this wealth of possible aetiological 
factors which may contribute to loss of asthma control, it is 
Table 2 Factors that may be responsible for poor asthma 
control Incorrect diagnosis 
Poor compliance/adherence to therapy
Psychosocial and emotional factors
Inadequate medical facilities
Poor access to medical facilities
Inadequate treatment
Exposure to allergens
Viral respiratory tract infections
Indoor/outdoor pollution
Gastro-oesophageal reﬂ  ux
Rhinosinusitis
Genetic factorsTherapeutics and Clinical Risk Management 2007:3(5) 774
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still not clear which of these can be clearly implicated in the 
genesis of glucocorticoid refractory or resistant asthma. It is 
furthermore not clear whether these aetiological factors lead 
to speciﬁ  c features of asthma pathology or contribute speciﬁ  -
cally to any feature of the natural history of the disease.
Environmental factors and “difﬁ  cult” asthma
Oxidative stress and anti-oxidants
Markers of oxidative stress such as 8-isoprostane are elevated 
in severe asthma (Katsoulis et al 2003; Kharitonov and Barnes 
2003). Cigarette smoking and poor dietary anti-oxidant 
intake are potential sources of oxidative stress, and it has 
been shown that asthmatics who smoke are clinically more 
resistant to glucocorticoid therapy (Chaudhuri et al 2003). 
Oxidative stress can affect several aspects of glucocorticoid 
activity, for example through activation of the transcriptional 
regulatory protein AP-1 or by reducing nuclear translocation 
of the glucocorticoid receptor (see below).
Viral and other infections
Recurrent respiratory tract infections, most of these viral, 
increase the risk of asthma exacerbation (ten Brinke et al 
2005), although it is not clear whether they alter responsive-
ness to glucocorticoid therapy. Very little is known about the 
mechanisms by which viral infections exacerbate asthma, 
and this ﬁ  eld deserves much more study. There is also some 
evidence for the involvement of latent chlamydial (Hahn 
et al 1991) and, at least in animal models, adenoviral infec-
tions (Yamada et al 2000).
Allergen exposure
There is abundant evidence (summarized by Leung and 
Bloom 2003; Busse et al 2005) that exposure of sensitized 
asthmatics to clinically relevant allergens requires increased 
glucocorticoid therapy for disease control. It has been shown 
(Nimmagadda et al 1997) that seasonal allergen exposure 
of atopic asthmatics increases refractoriness of their T cells 
to glucocorticoid in an allergen-speciﬁ  c and IL-2 and IL-4 
dependent fashion (see also below).
Microbial superantigens
There is evidence in other atopic diseases, particularly atopic 
dermatitis that colonization of the target organ (which is 
common) or infection with Staphylococcus aureus confers 
resistance to glucocorticoid therapy. Preferential expansion 
of T cells expressing particular antigen receptor Vβ chains 
has been observed in poorly controlled asthmatics (Hauk et al 
1999), suggesting activation by microbial superantigen. In 
addition to T cell activation, superantigen has been shown 
to confer T cell resistance to glucocorticoid by induction of 
the β-isoform of the glucocorticoid receptor and by phos-
phorylation of the glucocorticoid receptor (Hauk et al 2000; 
Li et al 2004).
The concept of glucocorticoid 
resistant asthma
The diagnosis of glucocorticoid resistant asthma is essen-
tially one of exclusion. Before it can be diagnosed, it must 
be ensured that the diagnosis of asthma is correct and that 
factors contributing to poor asthma control have been elimi-
nated as far as is possible. These stages have been formalized 
(Woolcock 1993) as follows:
• Establish/conﬁ  rm the diagnosis of asthma (consider dif-
ferential diagnosis – see Table 1);
•  Ensure that adequate dosages of glucocorticoids are 
reaching the airways (compliance, inhaler technique, 
metabolic factors which may increase glucocorticoid 
clearance);
•  Exclude ongoing exposure to provoking agents (smoke, 
irritants, allergens, etc.);
•  Rule out and eliminate as far as possible other potential 
aggravating conditions (chronic sinusitis, esophageal 
reﬂ  ux, drugs which may exacerbate asthma, etc.);
• Rationalize  inhaled  β2-agonist therapy;
•  Introduce a strict management plan to assess response to 
therapy which will typically last for weeks or sometimes 
months.
Even when all factors which may abrogate the effects 
of glucocorticoid therapy are eliminated or minimized as 
far as possible, there remains a group of patients who show 
little or no response of airways obstruction to glucocorticoid 
therapy. This concept was ﬁ  rst proposed over 30 years ago 
(Schwartz et al 1968). In this study, the authors described 
asthmatic patients in whom disease was poorly controlled, 
and the typical peripheral blood eosinopaenic response 
diminished, on large oral dosages of glucocorticoids. Later, 
it was recognised that there were some asthmatics in whom 
the diurnal pattern of airways obstruction is little altered by 
glucocorticoid therapy (Clark and Hetzel 1977).
The ﬁ  rst attempt to deﬁ  ne glucocorticoid resistant asthma 
in objective terms (Carmichael et al 1981) was based on 
changes in base line FEV1 following a 14 day course of oral 
prednisolone (40 mg/day). Patients showing improvements 
of 15% of baseline were classiﬁ  ed as resistant, whereas 
those showing improvements of 30% or more were con-
sidered glucocorticoid sensitive. All patients, in contrast, 
showed marked improvement in FEV1 in response to inhaled Therapeutics and Clinical Risk Management 2007:3(5) 775
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β2-agonists, indicating that, at least in this group of patients, 
the glucocorticoid response did not reﬂ  ect “irreversible” 
airways obstruction (although, as discussed, this may be 
a factor in other patients). Clearly, these FEV1 responses 
represent opposite ends of a continuum of clinical response. 
Most subsequent studies have employed deﬁ  nitions of glu-
cocorticoid sensitive and resistant asthma similar or identi-
cal to the above, in both adults and children (Kamada et al 
1992; Alvarez et al 1992). The possibility that glucocorticoid 
“resistant” subjects who show no clinical response following 
two weeks of oral glucocorticoid therapy might nevertheless 
respond following more protracted therapy has never been 
formally addressed, although it was shown (Kamada et al 
1993) that 90% of severe asthmatic children showing an 
improvement in FEV1 15% of baseline on high-dosage 
oral glucocorticoid therapy did so within 10 days.
On the basis of these studies, a workshop of experts on 
glucocorticoid resistant asthma proposed that this should 
be deﬁ  ned by the failure to improve baseline morning pre-
bronchodilator FEV1 by more than 15% of the baseline value 
following at least 14 days of therapy with prednisolone 
40 mg daily or its equivalent (Lee et al 1996). One weak-
ness of this deﬁ  nition is that patients with refractory asthma 
are typically taking large dosages of inhaled glucocorticoid, 
the therapeutic effect of which may have reached a “ceiling” 
limiting further clinical response. Nevertheless, patients with 
complete glucocorticoid resistance show not only a failure 
of response in terms of FEV1, but also, in general, an abil-
ity to tolerate reduction of glucocorticoid dosages without 
signiﬁ  cant change in disease activity. In addition, they typi-
cally show little increase in FEV1 even with more protracted, 
much higher dosages of systemic glucocorticoids. This is in 
distinction to glucocorticoid “dependent” asthmatics, who 
may not show a response in FEV1 of 15% or more during a 
14 day trial of systemic glucocorticoid therapy, but rapidly 
deteriorate when this therapy is withdrawn. Although it is 
assumed that these patients fall at the end and near end of a 
spectrum of glucocorticoid responsiveness in asthma, it is 
not certain whether these two groups of patients have fun-
damentally different abnormalities leading to glucocorticoid 
refractoriness. Although glucocorticoid resistant patients 
may show a degree of ﬁ  xed airways obstruction, many show 
marked diurnal variability in PEF and a brisk bronchodilator 
response (Alvarez et al 1992; Kamada et al 1992).
It is inherent in the diagnosis of glucocorticoid resistant 
asthma that the diagnosis of asthma has been made correctly 
and that factors confounding therapy have been eliminated 
or reduced as far as possible. Most clinical descriptions of 
glucocorticoid resistant asthma emphasize the following 
common clinical features (Spahn et al 1997):
•  Persistent symptoms despite optimal therapy;
• Chronic  airﬂ  ow limitation with FEV1 60% predicted 
in adults and 80% predicted in children;
•  Failure to achieve an increase in morning pre-bron-
chodilator FEV1 of 60% predicted despite systemic 
glucocorticoid therapy (at least 40 mg/day of predniso-
lone or its equivalent given for at least 14 days);
•  Frequent nocturnal symptoms with signiﬁ  cant “morning 
dipping” of PEF;
•  Poor clinical and spirometric response to oral glu-
cocorticoid therapy, with 15% improvement in 
pre-bronchodilator FEV1 following a trial of oral gluco-
corticoid therapy as speciﬁ  ed.
It should be noted ﬁ  nally that, although glucocorticoid 
resistant patients are identiﬁ  ed by deﬁ  nition on the basis of 
having severe disease which does not respond to therapy, it 
cannot be excluded that patients with milder disease may 
also nevertheless be glucocorticoid resistant. It would require 
a large and protracted study to investigate this hypothesis, 
but the point has a bearing on whether or not the severity of 
disease itself actually regulates, at least in part, glucocorticoid 
responsiveness (see below).
Mechanisms of glucocorticoid 
resistant asthma
Despite several decades of usage of glucocorticoids as anti-
inﬂ  ammatory agents, in general very little is known about 
the precise mechanisms by which they ameliorate inﬂ  amma-
tory diseases. A good review is provided by Ito et al (2006). 
Glucocorticoids exert a number of generalized anti-inﬂ  am-
matory activities, such as capillary vasoconstriction and 
reduction of vascular permeability, which may be relevant to 
suppression of inﬂ  ammation however caused. In the case of 
asthma, it is now generally accepted that bronchial mucosal 
inﬂ  ammation is a fundamental feature of disease pathogen-
esis. Despite the doubts about the precise roles (if any) of 
effector inﬂ  ammatory leukocytes discussed above, a working 
scenario is that eosinophils are regarded as pro-inﬂ  ammatory 
effector cells the products of which damage the bronchial 
mucosa, causing variable airways obstruction and bronchial 
hyperresponsiveness. Selective eosinophil accumulation and 
activation in asthma is in turn brought about by the release 
of eosinophil-active cytokines, particularly IL-3, IL-5 and 
GM-CSF, principally from activated T cells but also partly 
from other inﬂ  ammatory cells, including mast cells and 
eosinophils themselves (Corrigan and Kay 1992).Therapeutics and Clinical Risk Management 2007:3(5) 776
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If a mechanistic role for leukocytes such as eosinophils 
in asthma has become less clear recently, there remains 
much better evidence that glucocorticoid therapy which 
results in amelioration of asthma is associated with reduced 
activation of, and synthesis of asthma-relevant cytokines 
by activated T cells. For example, elevated percentages of 
peripheral blood CD4, but not CD8 T cells from patients 
with exacerbation of asthma expressed mRNA encoding 
IL-3, IL-5 and GM-CSF but not IL-2 and IFN-γ as compared 
with controls (Corrigan et al 1995). Spontaneous secretion of 
the corresponding cytokines was also demonstrable in these 
patients using an eosinophil survival-prolonging assay. The 
percentages of CD4 T cells expressing mRNA encoding 
asthma-relevant cytokines, as well as spontaneous secretion 
of these cytokines was reduced in association with glucocor-
ticoid therapy and clinical improvement. In a double-blind, 
parallel group study (Robinson et al 1993), therapy of mild 
atopic asthmatics with oral prednisolone, but not placebo, 
resulted in clinical improvement associated with a reduction 
in the percentages of BAL ﬂ  uid cells expressing IL-5 and IL-4 
and an increase in those expressing IFN-γ. These and other 
studies have provided overwhelming evidence in support of 
the general hypothesis that, in asthma, activated CD4 T cells 
secrete cytokines that are relevant to asthma pathogenesis, 
through direct actions on the airways mucosa or activation 
of inﬂ  ammatory leukocytes such as eosinophils, and that 
glucocorticoids exert their anti-asthma effect at least partly 
by reducing the synthesis of cytokines by these cells.
Functional T cell abnormalities 
in glucocorticoid resistant asthma
A reasonable hypothesis is, then, that glucocorticoid resistant 
asthma may reﬂ  ect refractoriness of T cells to glucocorticoid 
inhibition. A pioneering study in this ﬁ  eld (Poznansky et al 
1984) showed that when peripheral blood mononuclear cells 
from glucocorticoid sensitive and resistant asthmatics were 
cultured with the T cell mitogen phytohaemagglutinin (PHA) 
in soft agar in vitro, methylprednisolone (10−8 M) produced 
a lesser degree of inhibition of colony formation by the cells 
from the resistant asthmatics, suggesting impaired T cell inhi-
bition by glucocorticoids in these patients. This observation 
was followed up with two reports from the author’s labora-
tory (Corrigan et al 1991a, 1991b) characterizing peripheral 
blood T cells of glucocorticoid sensitive and resistant asth-
matics. In summary, it was demonstrated in these reports that 
PHA-induced proliferation of peripheral blood T cells was 
inhibited by dexamethasone at therapeutic concentrations in 
glucocorticoid sensitive, but not resistant asthmatics. This 
resistance was not absolute but relative, reﬂ  ecting a shift 
in the concentration-response curve for inhibition. In other 
words, T cells from glucocorticoid resistant asthmatics can 
be inhibited by glucocorticoids, but only at concentrations 
requiring glucocorticoid dosages that most physicians would 
not contemplate using for protracted periods in clinical prac-
tice. Consistent with this, it was demonstrated (Corrigan et al 
1991b) that elevated percentages of peripheral blood T cells 
expressed the activation markers in CD25 and HLA-DR in 
glucocorticoid resistant, as compared with sensitive asthmat-
ics, with no differences in total cell numbers, suggesting 
persistent T cell activation in the resistant patients despite 
glucocorticoid therapy.
In glucocorticoid resistant asthmatics, clinical resistance 
to therapy could not be accounted for by differences in 
absorption and clearance of plasma prednisolone derived 
from orally administered prednisone. We have subse-
quently shown (Haczku et al 1994) that the inhibition of 
PHA-induced proliferation of peripheral blood T cells 
from asthmatics by glucocorticoids in vitro is reproducible 
both in the short term and when patients are re-tested after 
intervals of several months. This suggests that the degree of 
glucocorticoid sensitivity of peripheral blood T cells from 
asthmatics, and by inference their clinical sensitivity to glu-
cocorticoid therapy, remains relatively constant, although 
there is evidence (see below) that sensitivity in individual 
patients may vary to some degree according to the ongoing 
severity of their disease.
Glucocorticoid resistant asthmatics are not Addisonian 
and do not have elevated plasma cortisol concentrations 
(Corrigan et al 1991a), suggesting that the impaired gluco-
corticoid responsiveness observed in their peripheral blood 
T cells is not a generalised, systemic phenomenon. One pos-
sibility is that impaired T cell glucocorticoid responsiveness 
in asthma may be induced by the action of pro-inﬂ  ammatory 
cytokines within the local environment of the inﬂ  amma-
tory process. In this regard, there exists evidence that the 
glucocorticoid receptor ligand binding afﬁ  nity of peripheral 
blood T cells in asthmatics may be altered in the short term 
according to disease severity in vivo and by exposure to 
cytokines in vitro. The glucocorticoid receptor ligand binding 
afﬁ  nities of peripheral blood T cells from a group of poorly 
controlled asthmatics were reduced as compared with normal 
controls (median Kd 29.0 vs 8.0 nM). Glucocorticoid therapy 
of these asthmatics, which was accompanied by clinical 
improvement, was associated with a signiﬁ  cant increase in 
afﬁ  nity of the T cell glucocorticoid receptors (Spahn et al 
1995). In a detailed study of glucocorticoid receptor binding Therapeutics and Clinical Risk Management 2007:3(5) 777
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in peripheral blood mononuclear cells from glucocorticoid 
sensitive and resistant asthmatics, two distinct abnormalities 
were observed (Sher et al 1994). The majority of the asth-
matics (15 out of 17) demonstrated a signiﬁ  cantly reduced 
receptor binding afﬁ  nity (mean Kd 42.1 nM) as compared 
with sensitive patients (mean Kd 21.6 nM) and normal 
controls (mean Kd 7.9 nM). This abnormality was conﬁ  ned 
to T cells, reverted to normal after culture of the T cells in 
vitro for 48 hours, but could be sustained by culture in the 
simultaneous presence of high concentrations of IL-2 and 
IL-4. The remaining two glucocorticoid resistant asthmatics 
had abnormally low numbers of nuclear glucocorticoid recep-
tors with normal binding afﬁ  nity. This abnormality was not 
conﬁ  ned to T cells and was not inﬂ  uenced by the presence of 
exogenous cytokines. It was further shown (Kam et al 1993) 
that this abnormality could be induced by culture of periph-
eral blood T cells from normal donors with IL-2 and IL-4 in 
vitro, and that this induction was associated with a reduced 
inhibitory effect of methylprednisolone on the proliferation 
of the T cells induced by phorbol ester and ionomycin. A 
similar effect of exogenous IL-13 alone was subsequently 
demonstrated in monocytes (Spahn et al 1996). The intrinsic 
physiological signiﬁ  cance of these relatively small changes 
in ligand binding afﬁ  nity of the glucocorticoid receptor is 
difﬁ  cult to assess, but clearly they may contribute to gluco-
corticoid refractoriness. More likely, they may represent an 
epiphenomenon reﬂ  ecting more fundamental changes in the 
properties of the glucocorticoid receptor in T cells following 
exposure to cytokines (see below).
There exists similar evidence for a differential effect 
of glucocorticoids on T cells from sensitive and resistant 
asthmatics in vivo (Leung et al 1995). In this study, bron-
choalveolar lavage was performed in glucocorticoid sensitive 
and resistant asthmatics before and after a course of oral 
prednisone, and expression by BAL cells of mRNA encoding 
cytokines was measured by in situ hybridization. Whereas 
prednisone therapy of the glucocorticoid sensitive asthmatics 
was associated with reductions in the percentages of BAL 
cells expressing mRNA encoding IL-4 and IL-5 and elevation 
of the percentages of cells expressing mRNA encoding IFN-γ, 
only a decrease in the percentages of cells expressing mRNA 
encoding IFN-γ was observed in association with prednisone 
therapy of the glucocorticoid resistant asthmatics. In addi-
tion, compared with the sensitive asthmatics, the resistant 
patients had elevated percentages of BAL cells expressing 
mRNA encoding both IL-2 and IL-4 at baseline. These data 
are compatible with the hypothesis that glucocorticoids 
exert differential effects on cytokine mRNA expression in 
T cells from glucocorticoid sensitive and resistant asthmatics 
in vivo. The authors also speculated that the local elevated 
expression of IL-2 and IL-4, at least at the level of mRNA, 
in these patients might have been responsible for some of 
the glucocorticoid refractoriness of the cells described in the 
in vitro experiments above.
Although glucocorticoids generally reduce inﬂ  ammation 
by inhibiting the production of pro-inﬂ  ammatory cytokines, 
one interesting facet of glucocorticoid action, which is 
receiving increasing attention, is their ability to increase the 
production of the anti-inﬂ  ammatory cytokine interleukin-10 
(IL-10). Studies in patients, initially in transplantation (Wan 
et al 1996), and more recently in other conditions including 
asthma (John et al 1998), have demonstrated that administra-
tion of glucocorticoids, intravenously or by inhalation, results 
in a signiﬁ  cant increase in systemic or local IL-10 synthesis 
respectively. Parallel studies from our own laboratories 
have shown a concentration-dependent induction by gluco-
corticoids of T cell IL-10 expression in vitro (Richards et al 
2000). Interest in the possible therapeutic beneﬁ  t of IL-10 in 
asthma already exists, based on its proposed role in regulating 
immune homeostasis in the lung (Akbari et al 2001). IL-10 
inhibits pro-inﬂ  ammatory cytokine production, antigen pre-
sentation, T cell activation and mast cell and eosinophil func-
tion (reviewed by Moore et al 2001). Furthermore, synthesis 
of IL-10 is deﬁ  cient in the airways of asthmatics as compared 
with controls (Borish et al 1996), and polymorphisms of 
the IL-10 gene leading to impaired expression of IL-10 are 
associated with a more severe disease phenotype (Lim et al 
1998). We have recently described a marked deﬁ  ciency in 
the capacity of CD4+ T cells from glucocorticoid resistant 
asthmatics to synthesize IL-10 following in vitro stimulation 
in the presence of dexamethasone, as compared with sensi-
tive patients of equivalent disease severity (Hawrylowicz 
et al 2002). We have furthermore shown that vitamin D3 in 
combination with glucocorticoids can restore the ability of 
blood CD4 T cells from patients with glucocorticoid resistant 
asthma to manufacture IL-10 in quantities comparable with 
those of sensitive patients, and that oral administration of 
vitamin D3 to glucocorticoid resistant asthmatics for seven 
days enhanced ex vivo responses of their T cells to gluco-
corticoid (Xystrakis et al 2006).
Molecular basis of glucocorticoid action 
and resistance
Observations made in the past few years have greatly 
increased our knowledge of how the GR regulates tran-
scription, and how this process may be modified both Therapeutics and Clinical Risk Management 2007:3(5) 778
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in vitro and in vivo. The GR comprises three domains, the 
N-terminal or immunogenicity domain, the central DNA-
binding domain and the C-terminal ligand-binding domain 
(Kino and Chrousos 2001; Ito et al 2006). The GR in its 
ligand-unbound state is located primarily in the cytoplasm 
as part of hetero-oligomeric complexes containing the heat 
shock proteins 90, 70 and 50. Upon binding to ligand, the 
GR undergoes conformational changes, dissociates from 
the heat shock proteins, homodimerizes and translocates to 
the nucleus. There, the ligand-activated GR may interact 
with DNA sequences (glucocorticoid response elements) or 
with other transcriptional regulators through protein/protein 
interactions, directly inﬂ  uencing the activity of the latter on 
their target genes (Figure 1).
Proteins which may bind directly to the GR and modulate 
its activity in this way include AP-1, NFκB, signal transduc-
tion and activators of transcription (STATs) and certain of 
the CCAAT-enhancer binding proteins (C/EBP). These 
interactions appear to be particularly important in glucocor-
ticoid-mediated suppression of inﬂ  ammation, and may allow 
the activated GR to transrepress expression of cytokine genes 
without binding to DNA at all (Reichhardt et al 2001).
Interaction of GR with AP-1
The pro-inflammatory transcriptional element activator 
protein-1 (AP-1) is an important contributor to the expression 
of the asthma-relevant Th2 cytokines IL-4, IL-5 and IL-13. 
AP-1 comprises of variable heterodimers of Jun (c-Jun, JunB 
and JunD) and Fos (c-Fos, FosB, Fra1 and Fra2) family 
members. AP-1 is inducible by a variety of cytokines and 
growth factors (Lee et al 1987), and also by oxidative stress 
(see above). It is activated through the phosphorylation of 
c-Jun and the transcriptional regulation of c-Fos (Figure 2). 
Phosphorylation of c-Jun is the end result of the action of a 
Figure 1 Mechanism of glucocorticoid action.  After diffusion across the cytoplasmic membrane, glucocorticoid (GC) binds to the glucocorticoid receptor (GR) which 
dissociates from heat shock protein 90 (HSP90) then dimerises. In the cell cytoplasm it may interact with transcriptional regulatory proteins such as AP-1; such interactions 
are mutually inhibitory. Nuclear translocation of the ligand bound GR is regulated by chemical modiﬁ  cations, such as phosphorylation, and possibly other mechanisms. Once 
inside the nucleus, the ligand bound receptor may interact directly with binding regions (glucocorticoid regulatory elements, GRE) adjacent to genes, either increasing 
(A) or decreasing (B, negative GRE) transcription of these genes. More usually, however, the ligand-bound GR interacts with DNA as part of a highly dynamic complex of 
proteins including transcriptional regulatory proteins such as AP-1, NFκB and cyclic AMP response element binding protein (CREB) (see text). The complexity of these 
interactions in individual cells accounts for the remarkable variability of glucocorticoid actions on cells according to their function and phenotype.Therapeutics and Clinical Risk Management 2007:3(5) 779
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trilayer of kinases (English and Cobb 2002). c-Jun itself is 
phosphorylated by Jun-N-terminal kinase (JNK), a member 
of the extracellular signal-related kinases/mitogen-activated 
protein kinases (ERK/MAPK) family of serine/threonine 
kinases. JNK is in turn activated by phosphorylation by JNK 
kinase, a member of the MAPK/ERK kinase (MEK) family 
of kinases that phosphorylate on both a tyrosine and a threo-
nine or serine residue. Of the seven members of the MEK 
family, MEK4 or Jun-N-terminal kinase kinase is principally 
responsible for the phosphorylation of JNK. At the top end 
of the trilayer, the most upstream kinases in the cascade, are 
the MEK kinases (MEKK), serine/threonine kinases that are 
diverse in sequence and structure (Figure 3).
In collaboration with Professor Ian Adcock at Imperial 
College, London, we have implicated abnormal regulation 
of AP-1 in the mechanism of glucocorticoid resistance. 
We showed that glucocorticoid-exposed peripheral blood 
mononuclear cells from glucocorticoid-resistant, as com-
pared with glucocorticoid-sensitive asthmatics have fewer 
activated GR available for DNA binding (Adcock et al 
1995a), but elevated DNA binding of AP-1 following 
phorbol ester stimulation (Adcock et al 1995b). These cells 
also demonstrated signiﬁ  cantly elevated basal, as well as 
phorbol ester-stimulated, transcription and translation of 
c-Fos. Furthermore, phorbol ester stimulation of cells from 
glucocorticoid-sensitive patients induced a glucocorticoid-
resistant phenotype, which was associated with direct 
interaction between the activated GR and c-Fos, detected by 
co-immunoprecipitation (Lane et al 1998). Binding of GR 
to other pro-inﬂ  ammatory transcriptional activators (such as 
CREB and NFκB) was unaffected. We interpret these data to 
suggest that mononuclear cells from glucocorticoid-resistant 
asthmatics inappropriately over-express AP-1, which seques-
ters and neutralises activated GR, thus causing refractori-
ness to glucocorticoid-induced inhibitory responses. More 
recently we have shown that (Loke et al 2006) that systemic 
glucocorticoid therapy of glucocorticoid sensitive, but not 
resistant, asthmatics is associated with down-regulation of 
phosphorylation of both c-Jun and JNK within inﬂ  ammatory 
cells within the bronchial mucosa, further underlining a criti-
cal role for AP-1 components in regulating glucocorticoid 
response in asthma. The reason for this failure of glucocorti-
coid to down-regulate the c-Jun/JNK/MEK cascade in clini-
cally resistant patients is presently unclear, but may reﬂ  ect 
inﬂ  uences of the local cytokine milieu in these patients (such 
as elevated IL-2/IL-4 expression, as described above, which 
Figure 2 Regulation of activation of c-fos and c-jun, the components of AP-1. Transcription of c-fos is induced by serum response factor (SRF) which binds to the serum 
response element (SRE) adjacent to the c-fos gene. SRF is activated by phosphorylation by ELK-1, which is in turn activated by phosphorylation by a range of MAP kinases 
including ERK-1/2 and JNK (see text). Phosphorylated JNK also phosphorylates and activates c-jun, which together with c-fos forms the heterodimer complex AP-1.  AP-1 
increases the transcription of a number of asthma-relevant cytokine genes such as interleukin (IL)-4 and IL-5.  This activity is inhibited by interaction with the ligand bound 
glucocorticoid receptor (GR) (see text and Figure 1 above). IL-4 and IL-5 may in turn further stimulate MAP kinase activity, forming a positive, feed-forward loop. Many 
other stimuli, including oxidative stress may also activate MAP kinases.Therapeutics and Clinical Risk Management 2007:3(5) 780
Corrigan and Loke
may enhance AP-1 production (Wang et al 1994)) and/or the 
inﬂ  uences of environmental stimuli such as oxidative stress 
or microbial superantigens as described above.
The role of p38 MAP kinase
p38 MAP kinase is another member of the family of 
MAPK/ERK molecules. Its activity is regulated by phos-
phorylation, principally by the p38 MAP kinases MEK3 
and MEK6. A recent study (Irusen et al 2002) has raised 
the intriguing possibility that changes in the binding afﬁ  n-
ity of nuclear GR induced by exposure to IL-2/IL-4 may be 
caused by direct phosphorylation of the GR at serine 226 
secondary to the resulting activation of p38 MAP kinase. 
Although this study did not directly demonstrate that p38 
MAP kinase phosphorylation of the GR is responsible for its 
reduced binding afﬁ  nity for glucocorticoids or its defective 
induction of an inhibitory signal, the hypothesis is certainly 
plausible. Similarly TNF-α has been shown to induce glu-
cocorticoid resistance in normal human monocytes, possibly 
through activation of p38 MAP kinase in addition to NF-κB 
(Franchimont et al 1999). Several other protein kinases, such 
as JNK, may also modify activity of the GR in this way, either 
directly or through phosphorylation of co-factor molecules 
(Krstic et al 1997; Rogatsky et al 1998).
The ﬁ  ndings with p38 MAP kinase raise the possibility 
that the small alteration in ligand binding afﬁ  nity of the 
nuclear GR induced by IL-2/IL-4 exposure is an epiphenom-
enon reﬂ  ecting more fundamental alterations in the function 
of the GR brought about by phosphorylation. This is in line 
with the fact that the observed changes in ligand-binding 
afﬁ  nity of the GR are relatively small and of doubtful physi-
ological signiﬁ  cance per se. Such a fundamental alteration 
in GR function is also suggested by the fact that serine 226 
is located in the N-terminal domain of the GR, remote from 
the ligand-binding pocket which resides in the C-terminal 
portion of the molecule. There is some precedent for the 
Figure 3 The tri-layer of kinases which activate c-jun. Environmental cytokines, ultraviolet light, serum factors, oxidative stress and many other stimuli phosphorylate and 
activate MEKK-1/4 through the Ras/Rho family of small GTP-binding proteins as shown. MEKK1 in turn phosphorylates JNKK1, which phosphorylates JNK, which binds to 
and phosphorylates c-jun, the active component of AP-1 (see text and Figure 2 above), and the regulatory protein activating transcription factor-2 (ATF-2). Phosphorylation 
may occur on threonine or tyrosine residues.
Abbreviations: GT(D)P, guanosine tri(di)phosphate; JNK, c-jun N-terminal kinase; JNKK1, c-jun N-terminal kinase kinase-1; MEKK-1/4, MAPK/ERK kinase kinase-1/4; SAPK, 
serum activated protein kinase; Ser, serine; SOS, son of sevenless; Thr, threonine; Tyr, tyrosine.Therapeutics and Clinical Risk Management 2007:3(5) 781
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possibility that remote regions of the GR may mutually 
interact. For example, there are two trans-activation domains, 
activation functions (AF) 1 and 2, situated respectively in 
the immunogenic and DNA-binding domains of the GR, 
which co-contribute to the full activity of the GR molecule 
on its responsive promoters. Conceivably, phosphorylation 
at a remote site might effect such interactions. Furthermore, 
both AF1 and AF2 interact with several other nuclear proteins 
and protein complexes, such as members of the p160 family 
and the co-activators p300/cyclic AMP-responsive element-
binding protein (CREB)-binding protein (CRP) (Hittelman 
et al 1999) which can affect the glucocorticoid-titration 
response of GR transactivation of its responsive promoters 
(Szapary et al 1999).
The role of mitogen-activated extracellular 
signal-related kinases (MEK)
In one further recent study (Li et al 2004), stimulation of 
T cells with enterotoxin superantigen produced by Staphy-
lococcus aureus rendered them resistant to GC inhibition in 
vitro, and this was accompanied by phosphorylation of both 
the mitogen-activated extracellular signal-related kinase 
(MEK/ERK) signaling protein and the GC receptor itself, as 
well as its impaired nuclear translocation. Treatment of cells 
with MEK/ERK inhibitors abrogated all of these effects. The 
authors inferred that activation of the MEK/ERK signaling 
pathway renders T cells resistant to GC inhibition by direct, 
ERK-mediated phosphorylation of the GC receptor which 
impairs its nuclear translocation. The effects of external 
environmental factors such as staphylococcal coloniza-
tion on GC responsiveness emphasize the possibility that 
environmental factors may inﬂ  uence this responsiveness in 
individual patients.
The role of the GRβ-isoform
The β-isoform of the GR is a splice variant of the “normal” 
GR, or GRα. The splicing varies in the choice of a splice 
acceptor site in exon 9. The cDNA sequence up until this 
point encodes a common region of 727 amino acids. There-
after, the GRα splice adds 50 amino acids whereas the 
β isoform has only a further 15 residues. The consequence 
of this alternative splice was shown to be an inability of the 
β isoform to bind ligand (Oakley et al 1996). The reason for 
this has been clariﬁ  ed by the recent crystallization of the 
GR ligand-binding domain complexed with dexamethasone 
and a peptide that was homologous to the GR interaction 
domain of the co-activator TIF2 (Bledsoe et al 2002). This 
study demonstrated that the amino acids of the receptor bind 
to ligand through either hydrogen bonds or hydrophobic 
interactions. One residue forming a hydrogen bond (T739) 
and seven residues forming hydrophobic interactions (L732, 
Y735, C736, T739, I747, F749 and L753) are present within 
the α, but are absent from the β isoform.
Artiﬁ  cial transfection of cells with GRβ can inhibit GRα-
mediated stimulation of gene expression, [Oakley et al 1996; 
Webster et al 2001). The popular theory to explain this is 
that it acts as a dominant negative inhibitor of GRα activity 
(but see reservations below). Physiological expression of 
GRβ in neutrophils has been suggested as a possible cause 
of their relative refractoriness to glucocorticoid inhibition 
(Strickland et al 2001). Several studies suggest that GRβ 
may be induced in cell lines to an extent sufﬁ  cient to induce 
glucocorticoid resistance by pro-inﬂ  ammatory cytokines 
such as TNF-α (Webster et al 2001), possibly reﬂ  ecting 
the location of a consensus NF-κB binding sequence in the 
5-ﬂ  anking sequences of the GR gene. Furthermore, increased 
GRβ immunoreactivity has been reported in peripheral blood 
mononuclear cells and bronchoalveolar lavage cells from 
patients with glucocorticoid-resistant asthma (Hamid et al 
1999), although possible modulation of expression in associa-
tion with glucocorticoid therapy was not explored. In studies 
from our own laboratory using a model of tuberculin-induced 
cutaneous inﬂ  ammation, we reported elevated expression of 
GRβ immunoreactivity in inﬂ  ammatory cells inﬁ  ltrating the 
skin lesions in glucocorticoid resistant, as compared with 
sensitive asthmatics (Sousa et al 2000). Treatment of the 
patients with systemic glucocorticoids was associated with 
down regulation of GRα expression in the glucocorticoid 
sensitive, but not the resistant patients.
Notwithstanding these observations, it seems likely that 
there is much yet to be learned about the possible functional 
role of GRβ. In this context it is possible to speculate on how 
GRβ may inﬂ  uence transcriptional activation mediated by 
GRα and its binding to the glucocorticoid response element 
(GRE), transcriptional repression mediated by GRα binding 
to negative GREs and inhibition of transcriptional activation 
mediated by sequestration of transcription factors:
Effects of GRβ on transcriptional activation
In terms of transcriptional activation, the classical role of 
GRα is to bind ligand, to dimerize and then to bind to GRE. 
This binding permits the recruitment of co-activator com-
plexes, because one of the consequences of ligand binding for 
nuclear hormone receptors is a reduction in their afﬁ  nity for 
co-repressor complexes, and replacement of these complexes 
with co-activators. The crystallization data referred to above Therapeutics and Clinical Risk Management 2007:3(5) 782
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(Bledsoe et al 2002) indicate that GRβ lacks residues forming 
the charge clamp required for docking of the amino terminus 
TIF2 LXXLL motif, suggesting that GRβ may be unable 
to recruit co-factors required for transcriptional activation. 
Thus GRβ, by displacing GRα, could conceivably act as a 
dominant negative inhibitor of transcriptional activation. 
There are, however, uncertainties regarding this conclu-
sion. In the ﬁ  rst place, GRβ seems to be expressed in much 
lower quantities (typically 10- to 100-fold less, at least at the 
level of mRNA expression) than GRα. In the second place, 
whereas in the case of GRα ligand binding appears to be a 
prerequisite for nuclear translocation, it is not known what 
governs the cytoplasmic/nuclear partitioning of GRβ or if 
it is present in sufﬁ  cient quantities in the cellular nucleus. 
Finally, it is unlikely that GRβ could dimerise efﬁ  ciently, so 
that its ability to compete for binding with high afﬁ  nity to 
GREs is questionable.
Effects of GRβ on transcriptional repression
Repression mediated by ligand-bound GR is thought to occur 
through binding to atypical sites on DNA, for example non-
consensus NFAT/AP-1 sites, rather than binding to GREs. 
At these sites, it is thought that the conformation of the DNA 
binding site, and the inﬂ  uence of locally bound factors might 
cause the GR to adopt a structure that is not permissive for 
recruitment of co-activators, but rather permissive for recruit-
ment of co-repressors. There is at present no information 
as to whether or not GRβ can bind to such sites and, more 
importantly, recruit co-repressor complexes.
Inhibition of transcriptional activation mediated 
by sequestration of transcription factors
So far, there has been no clear demonstration for a role for 
the extreme carboxy-terminus of the GR in the sequestra-
tion (and inactivation) of transcriptional activating proteins 
such as AP-1. It is conceivable, therefore, that both GRα and 
GRβ could exert repressive effects on gene expression by 
sequestration of such transcriptional activators.
The possible role of histone proteins
DNA is packaged into chromatin, a highly organized and 
dynamic protein-DNA complex. The N-terminal tails of 
the core histone proteins contain highly conserved lysine 
residues that are sites for post-translational acetylation. 
Acetylation of histone residues results in unwinding of the 
DNA coiled around the histone core. This process opens up 
the chromatin structure, allowing transcriptional factors and 
RNA polymerase II to bind more readily to DNA, thereby 
increasing gene transcription (Imhof and Wolffe 1998). The 
large co-activator molecule CREB binding protein (CBP) 
that binds to the basal transcriptional apparatus has intrinsic 
histone acetyl transferase (HAT) activity. Additionally, 
associated co-activator proteins, including steroid receptor 
co-activator-1 (SRC-1), transcription factor intermediary 
factor–2 (TIF2), p300/CBP co-integrator-associated protein 
(p/CIP) and glucocorticosteroid receptor enhancing protein-1 
(GRIP-1) may enhance local HAT activity. In genes which 
are induced by glucocorticoids, high concentrations of 
glucocorticoids cause binding of the activated GR to CBP 
and/or associated co-activators, resulting in histone acetyla-
tion on lysines 5 and 16 of histone H4 and increased gene 
transcription. HAT activity may be further enhanced by 
binding of transcriptional regulatory proteins such as AP-1 
and NF-κB (Janknecht and Hunter 1996; Imhof and Wolffe 
1998). Repression of genes is conversely associated with a 
reversal of this process by histone deacetylation, mediated by 
histone deacetylases (HDACs) (Pazin and Kadonaga 1997). 
HDACs comprise of a growing family of enzymes of which 
at least 10 mammalian members have been described (Bertos 
et al 2001). Some, such as HDAC4 and HDAC8 are able to 
shuttle between the cellular nucleus and cytoplasm.
Histone acetylation is a dynamic process in which 
small changes in acetylase and deacetylase activity can 
considerably alter the net HAT activity at any particular 
gene promoter site. Suppression of HAT activity, as well 
as recruitment of HDAC activity to active transcriptional 
complexes may play a role in glucocorticoid regulation of 
gene transcription (Ito et al 2000). This may occur in a variety 
of ways. Glucocorticoid repression may reﬂ  ect competition 
between the activated GR and the binding sites on CBP 
for other transcriptional activating proteins, such as AP-1 
(Kamei et al 1996), NF-κB, Sp1, Ets, NF-AT and STATs, 
which may alter local HAT activity. Alternatively, and not 
exclusively, the GR may bind to one of several co-repressor 
molecules such as RIP140, NCoR1 and GRIP1which in turn 
associate with proteins having differing HAT activity (Ding 
et al 1998). These complex interactions probably play a major 
role in the genesis of the inﬁ  nitely variable and subtle effects 
of glucocorticoids on individual target cells.
Clearly, then, intrinsic abnormalities of, or external 
inﬂ  uences on the regulation of HAT activity in individual 
cells may inﬂ  uence their glucocorticoid responsiveness. 
Already there are suggestions that external inﬂ  uences such as 
exposure to cigarette smoke, an oxidative stress, may inhibit 
the anti-inﬂ  ammatory actions of glucocorticoids on cells in 
the lungs of smokers by reducing HDAC expression and Therapeutics and Clinical Risk Management 2007:3(5) 783
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activity (Ito et al 2005). Similar phenomena may contribute 
to glucocorticoid resistance in asthma.
Genetic basis of glucocorticoid resistance
The glucocorticoid receptor gene itself is a plausible candi-
date for a genetic basis to glucocorticoid resistance. A mis-
sense mutation in this gene had previously been found to be 
responsible for the phenomenon of familial glucocorticoid 
resistance (Hurley et al 1991). These patients have a markedly 
reduced afﬁ  nity of the glucocorticoid receptor for ligand and 
clinically have features of Addison’s disease, which is not 
the case with glucocorticoid resistant asthmatics. Analysis 
of the sequence of the glucocorticoid receptor protein in 
six resistant and sensitive patients showed no mutations in 
any of the subjects (Lane et al 1994). Although this work 
is ongoing, there is no obvious mutation that might account 
for glucocorticoid resistance. Obviously, relevant mutations 
do not necessarily have to be within the coding region of the 
receptor gene itself, but could be in genes encoding products 
in downstream signaling pathways.
In addition to this, glucocorticoid responsiveness may 
be governed at least partly by genetic factors. For example, 
one study suggested that inherited anomalies might render 
approximately 7% of the normal population relatively hyper-
sensitive to glucocorticoids (Lamberts et al 1996). Indeed, 
there is marked variability in the sensitivity of T cells even 
from normal individuals to glucocorticoid inhibition in vitro, 
suggesting that the phenomenon may not be induced entirely 
by inﬂ  ammation but may be partly heritable.
The technique of positional cloning provides a way to 
identify genes or gene complexes which predispose to disease 
in an unbiased fashion. Using this technique, ﬁ  ve genes or 
gene complexes (ADAM33, PHF11, DPP10, GPRA and 
SPINK5) have been linked with predisposition to asthma 
(reviewed by Cookson and Moffatt 2004), and studies are 
ongoing to investigate the functions of these genes, some 
of which, along with others to be discovered, may play a 
role in therapy resistant asthma. These studies involve large 
numbers of patients, but larger studies still will be needed 
to discern the relative contribution of genetics and environ-
ment in regulating asthma severity and responsiveness to 
therapy in individual patients. A further complication is 
that different genes may contribute variably to asthma in 
different racial groups.
The alternative approach to genetic analysis is to look 
for variability in the expression of “candidate genes” (that 
is, those hypothesized to be an important part of the disease 
process or in governing responsiveness to therapy), for 
example between asthmatics and controls or between gluco-
corticoid sensitive and resistant asthmatics. The list of such 
“candidate genes” is potentially very large, and the problem 
with this approach is that it is impossible to know the rela-
tive importance, and possible physiological signiﬁ  cance of 
any differences uncovered. This process is being facilitated 
by microarray gene ﬁ  ngerprinting, which allows analysis of 
the differential expression of potentially many thousands of 
genes on a single chip. Using this technique in an Icelandic 
population it was possible to deﬁ  ne a gene expression ﬁ  nger-
print which predicted glucocorticoid resistant, as compared 
with sensitive asthma not only in the population of origin 
but also in an independent cohort (Hakonarson et al 2005). 
Again such analysis might be confounded by ethnicity. Genes 
may also regulate drug metabolism variably in different 
individuals (Hall 1998).
Management of glucocorticoid resistant 
asthma
In view of the above, a proposed list of techniques for the 
investigation of “difﬁ  cult” asthma, including glucocorticoid 
resistant asthma, is proposed in Table 3. Such investigation 
would also include a formal trial of glucocorticoid therapy to 
investigate possible glucocorticoid resistance deﬁ  ned by the 
criteria discussed above. Key features of the management of 
severe asthma have much in common with the management 
of any patient with asthma. It is critical to make an accurate 
diagnosis, minimize factors which may induce loss of asthma 
control and ensure good compliance with therapy.
By deﬁ  nition, the “difﬁ  cult” asthmatic will be receiving 
high dosages of inhaled glucocorticoid therapy, often together 
with oral glucocorticoids. Generally all patients with severe 
asthma, particularly those admitted as an emergency will be 
treated with systemic glucocorticoids at high dosage for at 
least two weeks. It is only in the fullness of time that a pattern 
of glucocorticoid responsiveness is established. In patients 
thought to be truly glucocorticoid resistant (that is, patients 
showing the proscribed failure in FEV1 response when the 
diagnosis is conﬁ  rmed and aggravating conditions excluded), 
further long-term therapy with systemic glucocorticoids is 
probably inadvisable since there is little evidence that these 
drugs will inﬂ  uence asthmatic symptoms and disease activ-
ity, but may on the other hand cause considerable unwanted 
effects. In such cases it may be sensible to reduce or withdraw 
glucocorticoids and treat instead with adequate dosages 
of alternative anti-asthma drugs such as bronchodilators, 
leukotriene receptor antagonists and immunosuppressive 
drugs (see below). In clinical practice, however, because Therapeutics and Clinical Risk Management 2007:3(5) 784
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there is little hard evidence to justify withdrawal of systemic 
glucocorticoids from any severe asthmatic patient, this 
process is often ignored or delayed. Furthermore, it is not 
clear on clinical grounds whether glucocorticoid responsive-
ness is induced or enhanced by the use of glucocorticoids 
themselves (although reduction of asthmatic inﬂ  ammation 
would appear to be associated with an increased afﬁ  nity of 
the glucocorticoid receptor for binding to its ligand, as dis-
cussed above). In view of the possibility that glucocorticoid 
sensitivity may change with time, it would seem prudent to 
re-assess glucocorticoid sensitivity periodically (Demoly et al 
1998) although, as discussed above, within individuals T cell 
glucocorticoid sensitivity appears to be relatively stable at 
least over a period of months.
The observation that glucocorticoid responsiveness of 
asthmatics correlates with glucocorticoid inhibition of their 
T cells suggests that other drugs that inhibit T cells might 
be useful for asthma therapy, in particular drugs that inhibit 
T cells by mechanisms distinct from those of glucocorticoids. 
We have shown (Corrigan et al 1991b; Haczku et al 1994) 
that the immunosuppressive drugs cyclosporin A, rapamycin 
and mycophenolate mofetil inhibit proliferation of T cells 
from glucocorticoid sensitive and resistant asthmatics to an 
equivalent extent. It has been shown (Alexander et al 1992; 
Lock et al 1996) that cyclosporin A, when administered to 
patients with poorly controlled asthma despite continuous 
systemic glucocorticoid therapy, improved lung function 
while allowing reduction of oral glucocorticoid dosages in 
a proportion of the patients. Similarly concomitant therapy 
of glucocorticoid dependent asthmatics with methotrex-
ate (Shiner et al 1990) or gold salts (Klaustermeyer et al 
1987) has been shown in some trials to spare glucocorticoid 
therapy, although no trials have suggested that these agents 
improve lung function. In general, none of these agents is 
particularly satisfactory in the sense that many patients fail 
to respond and it is impossible to predict responsiveness a 
priori. Furthermore, chronic immunosuppression raises the 
risk of development of serious infection or malignancy, and 
there is in addition a list of not insigniﬁ  cant unwanted effects 
associated, in some patients, with the use of each particular 
drug. An urgent appraisal of other immunosuppressive drugs 
or cytokine inhibitory strategies is needed in glucocorticoid 
dependent and glucocorticoid resistant asthma. It is a prior-
ity to produce a global deﬁ  nition of which patients are suit-
able for treatment, and what constitutes an adequate trial of 
therapy. It will also be essential to develop cheap and reliable 
biomarkers of airways inﬂ  ammation and remodeling so that 
glucocorticoid responsiveness can be assessed accurately 
and objectively in the short and long term.
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